These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11357554)

  • 41. Sirolimus: a comprehensive review.
    Kahan BD
    Expert Opin Pharmacother; 2001 Nov; 2(11):1903-17. PubMed ID: 11825325
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range.
    Kovarik JM; Kaplan B; Tedesco Silva H; Kahan BD; Dantal J; Vitko S; Boger R; Rordorf C
    Transplantation; 2002 Mar; 73(6):920-5. PubMed ID: 11923693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.
    Kahan BD
    Lancet; 2000 Jul; 356(9225):194-202. PubMed ID: 10963197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Everolimus].
    Michels G; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(40):2263-5. PubMed ID: 16208601
    [No Abstract]   [Full Text] [Related]  

  • 46. Monitoring of immunosuppressive therapy in renal transplanted patients.
    Chiaramonte S; Dissegna D; Ronco C
    Contrib Nephrol; 2005; 146():73-86. PubMed ID: 15567922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience.
    Kahan BD; Knight R; Schoenberg L; Pobielski J; Kerman RH; Mahalati K; Yakupoglu Y; Aki FT; Katz S; Van Buren CT
    Transplant Proc; 2003 May; 35(3 Suppl):25S-34S. PubMed ID: 12742465
    [No Abstract]   [Full Text] [Related]  

  • 48. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y; Shi Y; Huang Z; Bai Y; Niu Q; Cai B; Wang L; Feng W
    Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ; Kerman RH; McKissick E; Lawless A; Podder H; Katz S; Van Buren CT; Kahan BD
    Clin Transplant; 2008; 22(5):645-50. PubMed ID: 18657156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can acute rejection be prevented in SPK transplantation?
    Burke G; Ciancio G; Figueiro J; Olson L; Gomez C; Rosen A; Suzart K; Miller J
    Transplant Proc; 2002 Aug; 34(5):1913-4. PubMed ID: 12176626
    [No Abstract]   [Full Text] [Related]  

  • 51. Experience with sirolimus for calcineurin minimization/elimination in pancreas-after-kidney transplantation.
    Gautam A; Morrissey PE; Gohh R; Yango A; Monaco AP
    Transplant Proc; 2005 Oct; 37(8):3542-3. PubMed ID: 16298654
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppressive drugs for kidney transplantation.
    Halloran PF
    N Engl J Med; 2004 Dec; 351(26):2715-29. PubMed ID: 15616206
    [No Abstract]   [Full Text] [Related]  

  • 53. Sirolimus antirejection therapy for renal transplantation with cyclosporine-based immunosuppression: case reports.
    Tsai MK; Hu RH; Lee PH
    Transplant Proc; 2003 Feb; 35(1):219-20. PubMed ID: 12591371
    [No Abstract]   [Full Text] [Related]  

  • 54. Sirolimus rescue therapy for refractory rejection in renal transplant recipients.
    Hong JC; Kahan BD
    Transplant Proc; 2001; 33(1-2):1033. PubMed ID: 11267178
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity.
    Kahan BD; Napoli KL; Kelly PA; Podbielski J; Hussein I; Urbauer DL; Katz SH; Van Buren CT
    Clin Transplant; 2000 Apr; 14(2):97-109. PubMed ID: 10770413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL; Cortese C; Geiger XJ; Younan K; Wadei HM; Mai ML; Reddy KS; Gonwa TA
    Transplantation; 2012 Jan; 93(1):47-53. PubMed ID: 22067270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y
    Transplant Proc; 2009; 41(6 Suppl):S39-41. PubMed ID: 19651295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.